Sosyal Fobi Nedeni İle Meydana Gelen Senkop Ciddi Ventriküler Aritminin Bir Göstergesi Olabilir

Year 2019, Volume: 7 Issue: Ek - IRUPEC 2019 Kongresi Tam Metin Bildirileri, 479 - 482, 10.12.2019

Fatih Şap , Muhammed Güneş

Abstract

Catecholaminergic polymorphic ventricular tachycardia is a rare inheritable cardiac channelopathy characterized by malignant polymorphic ventricular tachycardias that are triggered by catecholaminergic stress. During physical exercise or emotional stress, patients typically encounter syncope or sudden cardiac death within the first two decades of life. Here, we report the case of a nine-year-old female patient suffered from syncope due to feeling fear or anxiety to enter crowded environments. She was examined and followed up by several other departments, however no significant improvement of her symptoms was observed and then referred to our clinic. Catecholaminergic polymorphic ventricular tachycardia was detected at the end of cardiac examinations and successfully treated with propranolol. In patients with recurrent syncope attacks and dizziness, rhythm disturbances should be kept in mind that if it occurs especially after effort or emotional stress.

Keywords

Dizziness, Emotional stress, Syncope, Ventricular tachycardia

References

• References 1- Spears DA, Gollob MH, Genetics of inherited primary arrhytmia disorders. Appl Clin Genet 2015;8:215-33. 2- Reid DS, Tynan M, Braidwood L, Fitzgerald GR. Bidirectional tachycardia in a child. A study using His bundle electrography. Br Heart J 1975;37(3):339-44. 3- Laitinen PJ, Brown KM, Piippo K et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001;103(4):485-90. 4- George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003;93(6):531-40. 5- Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91(5):1512-9. 6- Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner’s cases. Mayo Clin Proc 2004;79(11):1380-4. 7- Roston TM, Vinocur JM, Maginot KR et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol 2015;8(3):633–42. 8- Priori SG, Napolitano C, Memmi M et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106(1):69-74. 9- Hayashi M, Denjoy I, Extramiana F et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009;119(18):2426-34. 10- Priori SG, Wilde AA, Horie M et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;10(12):1932-63. 11- Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug induced QT prolongation and torsade de pointes. Am Heart J 2007;153(6):891-9. 12- Roden DM. Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21(5):1029-34.